Abstract
Chronic non-healing wounds (CNHWs) may be associated with trauma or idiopathic in nature and are difficult to treat. Our objective was to assess the use of platelet-derived growth factor (PDGF) from single-donor platelets (al-PRP), using one freeze-thaw cycle, for treating CNHWs. We conducted a cross-sectional study. A total of 23 CNHWs being treated with al-PRP. The al-PRP treatment can be considered successful in well over half (n = 13, 56.5%) of the wounds. We found that all the wounds treated for up to 7 weeks showed partial or complete healing, while those treated for between 8 and 12 weeks did not show healing, healing again being successful in cases in which treatment was extended to more than 13 weeks (85.7%). Using chi-square tests, this relationship was found to be highly significant (p < 0.001, chi2 = 19.51; p value = 0.00006). Notably, Cramer’s V coefficient was very high (0.921), indicating that the effect size of PRP treatment duration on healing is very large (84.8%). We could suggest that the use of al-PRP in the healing of CNHWs is a promising approach. Further studies with larger sample sizes and long follow-ups are needed to obtain multivariate models to explain which factors favour the healing of ulcers treated with PRP
Highlights
[9] Seeking to optimise conditions for these events, several novel approaches have been proposed for the treatment of these wounds, including the use of platelet-rich plasma (PRP)
PRP contains concentrated platelets; it is usually prepared from whole blood by centrifugation, and while the focus has initially been on autologous platelet-rich plasma, there is growing interest in allogeneic platelet-rich plasma
Among patients recruited by the Transfusion Unit to start this treatment with al-PRP, seven were referred from the Haematology Unit, six with a haematological diagnosis of chronic myeloproliferative disorders such as essential thrombocythemia (ET) or polycythaemia vera (PV) treated with hydroxyurea, and one with a diagnosis of non-Hodgkin lymphoma
Summary
Introduction with regard to jurisdictional claims in Chronic non-healing wounds (CNHWs) may be associated with trauma or idiopathic in nature and are difficult to treat [1,2] Their worldwide prevalence is estimated to be as high as 0.5–1% and they are known to be associated with high morbidity and mortality, impairing patients’ mobility and quality of life quality of life, causing ill-heath related absence from work (with some 6 million working days lost per year in the USA) and generating high healthcare costs (over 5 billion dollars per year in the USA) [3–6]. Used in the fields of tissue engineering and regenerative medicine, the potential benefits of PRP include a positive effect on migration, proliferation and angiogenesis in in vitro as well as animal and human-based studies [9–12]. PRP contains concentrated platelets; it is usually prepared from whole blood by centrifugation, and while the focus has initially been on autologous platelet-rich plasma (au-PRP), there is growing interest in allogeneic (al-PRP) platelet-rich plasma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
